Gary Schiller, MD
For the past 30 years, standard treatment for both acute and chronic graft-versushost disease (GVHD) has focused on corticosteroid regimens that are often ineffective and lead to disabling side effects or mortality.
“Overall, we are better positioned to further understand the biology and identify the role of new pharmacologic interventions and how they can intersect with the pathogenesis of chronic GVHD,” said Pavletic.
Selective Targeting of T-Cell Activation
Acute GVHD presents an inflammatory phenotype, usually within the first few months of allogeneic stem cell transplantation, on the skin, liver, and gastrointestinal tract.
... to read the full story